This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Fatty Liver and Obstructive Sleep Apnea

This study has been completed.
Information provided by:
Assaf-Harofeh Medical Center Identifier:
First received: August 6, 2008
Last updated: August 7, 2008
Last verified: August 2008
Non-alcoholic fatty liver disease is associated with obstructive sleep apnea. Abnormalities in liver enzymes can improve following continuous positive airway pressure in patients with obstructive sleep apnea. Computerized tomography can be used to quantify fatty liver changes. We hypothesize that continuous positive airway pressure can reduce morphologic fatty liver changes in patients with obstructive sleep apnea and non-alcoholic fatty liver, an that this reduction can be evident using computerized tomography

Condition Intervention
Non-Alcoholic Fatty Liver Disease Obstructive Sleep Apnea Device: Continuous positive airway pressure

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Fatty Liver and Obstructive Sleep Apnea

Resource links provided by NLM:

Further study details as provided by Assaf-Harofeh Medical Center:

Primary Outcome Measures:
  • Reduction in fatty liver changes on computerized tomography [ Time Frame: Within 1-2 years ]

Secondary Outcome Measures:
  • Improved liver enzymes abnormalities [ Time Frame: Within 1-2 years ]

Arms Assigned Interventions
Experimental: A
continuous positive airway pressure
Device: Continuous positive airway pressure


Ages Eligible for Study:   30 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Obstructive sleep apnea, defined as AHI>5/h

Exclusion Criteria:

  • Consumption of more than 20 grams of alcohol per 24 h
  • Known autoimmune disease
  • Usage of known hepatotoxic drugs
  • Medical history positive for viral hepatitis or other chronic liver disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00730873

The pulmonary institute, Asaf Harofeh Medical Center
Zerifin, Israel, 70300
Sponsors and Collaborators
Assaf-Harofeh Medical Center
  More Information Identifier: NCT00730873     History of Changes
Other Study ID Numbers: 135/07
Study First Received: August 6, 2008
Last Updated: August 7, 2008

Additional relevant MeSH terms:
Sleep Apnea Syndromes
Sleep Apnea, Obstructive
Liver Diseases
Fatty Liver
Non-alcoholic Fatty Liver Disease
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms
Sleep Disorders, Intrinsic
Sleep Wake Disorders
Nervous System Diseases
Digestive System Diseases processed this record on August 18, 2017